Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurofilament Light Chain Protein and Remazolam Sensitivity in Older Adults
NCT07280663Phase 1Completed
- Sponsor
- The Second Hospital of Shanxi Medical University
- Start
- Oct 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of remimazolam mesylate in sedation (2 arms), sponsored by The Second Hospital of Shanxi Medical University. Primary endpoints: Neurofilament light chain protein at 24 hours, Loss of consciousness time at 24 hours and 6 more. Started Oct 2025; status: completed.
02
Drugs
remimazolam mesylate
03
Conditions
sedation
Beyond the preview
Go deeper on NCT07280663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07280663.